Disclosed herein is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an active agent selected from R-(+)-N-propargyl-1-aminoindan (rasagiline), S-(-)-N-propargyl-1-aminoindan, or a pharmaceutically acceptable salt thereof, formulated for extended release of said active agent. Additionally disclosed is an extended release pellet, a method of preparing said pellet and the use in the treatment of a neurodegenerative disease or an injury to the nervous system.
